Hurd,Yasmin, Ph.D. Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2010
NCT01311778
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Hurd,Yasmin, Ph.D.

Active Ingredients

Drugs in Phase 2 Trials (1)

cannabidiol (Epidiolex) (6 trials)

Drugs in Phase 1 Trials (1)

fentanyl (Innovar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 2)

Heroin Dependence (Phase 2)

Opioid-Related Disorders (Phase 2)

Substance-Related Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2